Targeting specific structures in protein aggregates linked to diseases
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates
This study is looking at how certain proteins can clump together in ways that might cause diseases like Alzheimer's, and it's working on creating special tools to help doctors spot these clumps and find better ways to treat these conditions, which could really help patients in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10814389 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins aggregate in different forms, which can lead to various diseases, including neurodegenerative disorders. By developing specialized antibodies that can recognize these unique protein structures, the research aims to create tools for diagnosing and potentially treating these conditions. The approach involves generating antibodies that can specifically bind to different conformations of amyloidogenic aggregates, allowing for a better understanding of their roles in disease. Patients may benefit from advancements in diagnostic and therapeutic strategies that arise from this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by neurodegenerative diseases or conditions linked to amyloidogenic protein aggregation.
Not a fit: Patients with non-amyloidogenic conditions or those not affected by protein aggregation-related diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for diseases associated with protein aggregation.
How similar studies have performed: Previous research has shown promise in using antibodies to target protein aggregates, indicating that this approach may lead to significant advancements in understanding and treating related diseases.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Tessier, Peter M — University of Michigan at Ann Arbor
- Study coordinator: Tessier, Peter M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.